Harrow Health Inc. 11.875... (HROWM)
Harrow Health 11.875% Senior Notes due 2027 Statistics
Share Statistics
Harrow Health 11.875% Senior Notes due 2027 has 41.28M shares outstanding. The number of shares has increased by 163.39% in one year.
Shares Outstanding | 41.28M |
Shares Change (YoY) | 163.39% |
Shares Change (QoQ) | -20.49% |
Owned by Institutions (%) | n/a |
Shares Floating | 35.64M |
Failed to Deliver (FTD) Shares | - |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 0, so 0% of the outstanding shares have been sold short.
Short Interest | 0 |
Short % of Shares Out | 0% |
Short % of Float | 0% |
Short Ratio (days to cover) | 0 |
Valuation Ratios
The PE ratio is -34.47 and the forward PE ratio is null. Harrow Health 11.875% Senior Notes due 2027's PEG ratio is undefined.
PE Ratio | -34.47 |
Forward PE | n/a |
PS Ratio | 6.46 |
Forward PS | null |
PB Ratio | 11.89 |
P/FCF Ratio | 353.58 |
PEG Ratio | undefined |
Enterprise Valuation
Harrow Health Inc. 11.875% Senior Notes due 2027 has an Enterprise Value (EV) of 957.93M.
EV / Earnings | -39.24 |
EV / Sales | 7.36 |
EV / EBITDA | 98.52 |
EV / EBIT | 2222.58 |
EV / FCF | 402.49 |
Financial Position
The company has a current ratio of 2.82, with a Debt / Equity ratio of 2.69.
Current Ratio | 2.82 |
Quick Ratio | 2.6 |
Debt / Equity | 2.69 |
Total Debt / Capitalization | 72.91 |
Cash Flow / Debt | 0.02 |
Interest Coverage | 0.02 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is 0.17%.
Return on Equity (ROE) | -0.34% |
Return on Assets (ROA) | -0.08% |
Return on Capital (ROIC) | 0.17% |
Revenue Per Employee | $599,967.74 |
Profits Per Employee | $-112,493.09 |
Employee Count | 217 |
Asset Turnover | 0.42 |
Inventory Turnover | 3.65 |
Taxes
Income Tax | 701K |
Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.17, so Harrow Health 11.875% Senior Notes due 2027's price volatility has been higher than the market average.
Beta | 0.17 |
52-Week Price Change | null% |
50-Day Moving Average | 26.34 |
200-Day Moving Average | 26.36 |
Relative Strength Index (RSI) | 48.02 |
Average Volume (20 Days) | - |
Income Statement
In the last 12 months, Harrow Health 11.875% Senior Notes due 2027 had revenue of 130.19M and earned -24.41M in profits. Earnings per share was -0.75.
Revenue | 130.19M |
Gross Profit | 90.55M |
Operating Income | 431K |
Net Income | -24.41M |
EBITDA | 9.72M |
EBIT | 431K |
Earnings Per Share (EPS) | -0.75 |
Balance Sheet
The company has 74.08M in cash and 190.5M in debt, giving a net cash position of -116.42M.
Cash & Cash Equivalents | 74.08M |
Total Debt | 190.5M |
Net Cash | -116.42M |
Retained Earnings | -133.9M |
Total Assets | 306.63M |
Working Capital | 85.39M |
Cash Flow
In the last 12 months, operating cash flow was 3.84M and capital expenditures -1.46M, giving a free cash flow of 2.38M.
Operating Cash Flow | 3.84M |
Capital Expenditures | -1.46M |
Free Cash Flow | 2.38M |
FCF Per Share | 0.07 |
Margins
Gross margin is 69.55%, with operating and profit margins of 0.33% and -18.75%.
Gross Margin | 69.55% |
Operating Margin | 0.33% |
Pretax Margin | -18.21% |
Profit Margin | -18.75% |
EBITDA Margin | 7.47% |
EBIT Margin | 0.33% |
FCF Margin | 1.83% |
Dividends & Yields
HROWM does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for HROWM.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | 2.78 |
Piotroski F-Score | 3 |